Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity

Liad Hinden*, Rami Ludyansky, Sary Leidershnaider, Yoav Harris, Alina Nemirovski, Ofer N. Gofrit, Joseph Tam, Guy Hidas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: The endocannabinoid system (ECS) plays a key physiological role in bladder function and it has been suggested as a potential target for relieving lower urinary tract symptoms (LUTSs). Whereas most studies indicate that activating the ECS has some beneficial effects on the bladder, some studies imply the opposite. In this study, we investigated the therapeutic potential of peripheral cannabinoid-1 receptor (CB1R) blockade in a mouse model for LUTSs. Materials and Methods: To this end, we used the cyclophosphamide (CYP; 300 mg/kg, intraperitoneal)-induced cystitis model of bladder dysfunction, in which 12-week-old, female C57BL/6 mice were treated with the peripherally restricted CB1R antagonist, JD5037 (3 mg/kg), or vehicle for three consecutive days. Bladder dysfunction was assessed using the noninvasive voiding spot assay (VSА) as well as the bladder-to-body weight (BW) ratio and gene and protein expression levels; ECS tone was assessed at the end of the study. Results: Peripheral CB1R blockade significantly ameliorated the severity of CYP-induced cystitis, manifested by reduced urination events measured in the VSА and an increased bladder-to-BW ratio. Moreover, JD5037 normalized CYP-mediated bladder ECS tone imbalance by affecting both the expression of CB1R and the endocannabinoid levels. These effects were associated with the ability of JD5037 to reduce CYP-induced inflammatory response, manifested by a reduction in levels of the proinflammatory cytokine, tumor necrosis factor alpha (TNFα), in the bladder and serum. Conclusions: Collectively, our results highlight the therapeutic relevance of peripheral CB1R blockade in ameliorating CYP-induced cystitis; they may further support the preclinical development and clinical use of peripherally restricted CB1R antagonism for treatment of LUTSs.

Original languageAmerican English
Pages (from-to)623-633
Number of pages11
JournalCannabis and Cannabinoid Research
Issue number4
StatePublished - 1 Aug 2023

Bibliographical note

Publisher Copyright:
© Liad Нinden et al. 2022;


  • cannabinoid-1 receptor
  • cyclophosphamide
  • cystitis
  • endocannabinoid system
  • lower urinary tract symptoms


Dive into the research topics of 'Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity'. Together they form a unique fingerprint.

Cite this